Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and effectiveness of three doses of CKD-501
compared to placebo in lowering fasting plasma glucose levels in people with type 2 diabetes
for 8 weeks.